High-Purity Omeprazole Intermediate: Your Trusted Manufacturer and Supplier

Discover the essential Omeprazole intermediate (CAS 73590-58-6), a cornerstone for synthesizing vital gastrointestinal pharmaceuticals. Sourced from leading manufacturers in China, we ensure unparalleled quality and competitive pricing for your procurement needs.

Get a Quote & Sample

Why Choose Our Omeprazole Intermediate?

Uncompromising Quality Assurance

Our Omeprazole Intermediate adheres to the CP2015 standard, with rigorous testing for appearance, related substances, and residual solvents, ensuring pharmaceutical-grade quality. When you buy Omeprazole intermediate, you are guaranteed a product designed for sensitive API synthesis.

Reliable Supply Chain & Competitive Pricing

As a prominent manufacturer and supplier in China, we offer competitive pricing for Omeprazole Intermediate. Secure your procurement needs with a partner committed to consistent availability and timely delivery of this essential pharmaceutical chemical.

Technical Expertise & Support

Leverage our deep understanding of pharmaceutical intermediates. We provide comprehensive product details and support to ensure seamless integration of our Omeprazole Intermediate into your manufacturing processes. Inquire about bulk purchase options and get a quote today.

Key Applications of Omeprazole Intermediate

Pharmaceutical API Synthesis

This Omeprazole intermediate (CAS 73590-58-6) is a critical building block for the synthesis of Omeprazole Active Pharmaceutical Ingredient (API), a widely used medication.

Proton Pump Inhibitors (PPIs)

Essential for producing PPIs that effectively inhibit gastric acid secretion, offering relief for conditions like peptic ulcers and gastroesophageal reflux disease (GERD).

Gastrointestinal Treatments

The synthesis of drugs targeting gastrointestinal disorders relies heavily on the availability of high-quality intermediates like this Omeprazole compound.

Research & Development

Valuable for pharmaceutical R&D departments exploring new formulations or synthesis pathways for gastric acid-reducing medications.